Andrea Decensi
European Institute of Oncology
Publications 230
#1N. ColomboH-Index: 28
Last.Elena BiagioliH-Index: 7
view all 19 authors...
#1Andrea DecensiH-Index: 36
#2Matteo PuntoniH-Index: 10
Last.Bernardo Bonanni (IEO: European Institute of Oncology)H-Index: 46
view all 20 authors...
1500Background: Low-dose tamoxifen (babytam) at 5 mg/day for 3 years decreases local or contralateral recurrence by 52% in women with hormone sensitive breast pre-invasive neoplasia after surgery (...
#1Mohamed Elgendy (IEO: European Institute of Oncology)H-Index: 11
#2Marco CiroH-Index: 8
Last.Saverio Minucci (IEO: European Institute of Oncology)H-Index: 59
view all 19 authors...
Summary Tumor cells may adapt to metabolic challenges by alternating between glycolysis and oxidative phosphorylation (OXPHOS). To target this metabolic plasticity, we combined intermittent fasting, a clinically feasible approach to reduce glucose availability, with the OXPHOS inhibitor metformin. In mice exposed to 24-h feeding/fasting cycles, metformin impaired tumor growth only when administered during fasting-induced hypoglycemia. Synergistic anti-neoplastic effects of the metformin/hypoglyc...
9 CitationsSource
#1Andrea DecensiH-Index: 36
#2Andreas J. Gescher (University of Leicester)H-Index: 54
A recent article published in The Lancet reports on the seAFOod trial, in which patients with colorectal adenomas received aspirin and/or eicosapentaenoic acid (EPA, an omega-3 polyunsaturated fatty acid) post-resection. The article9s abstract indicates that the primary trial endpoint, adenoma detection rate, is negative, but it does not give any indication of the remarkable secondary endpoint (adenoma number) results, which strongly suggest chemopreventive efficacy of both agents. Given the dif...
The crosstalk between cancer cells and host cells is a crucial prerequisite for tumor growth and progression. The cells from both the innate and adaptive immune systems enter into a perverse relationship with tumor cells to create a tumor-promoting and immunosuppressive tumor microenvironment (TME). Epithelial ovarian cancer (EOC), the most lethal of all gynecological malignancies, is characterized by a unique TME that paves the way to the formation of metastasis and mediates therapy resistance ...
4 CitationsSource
#1Stefania GoriH-Index: 21
#2Fabio PuglisiH-Index: 34
Last.Lucia Del MastroH-Index: 24
view all 13 authors...
Abstract Premenopausal women with hormone receptor-positive early breast cancer are candidates for adjuvant endocrine therapy, as recommended by the major international guidelines. To date, adjuvant endocrine options for premenopausal women include tamoxifen with or without ovarian function suppression (OFS) or an aromatase inhibitor with OFS. Multiple strategies for endocrine treatment of premenopausal women with hormone-responsive breast cancer have been assessed, and the results of randomised...
1 CitationsSource
#1Serena PatroneH-Index: 1
#2Irena MaricH-Index: 3
Last.Domenico CovielloH-Index: 26
view all 19 authors...
3 CitationsSource
#1Debora Macis (IEO: European Institute of Oncology)H-Index: 11
#2Ivana Sestak (QMUL: Queen Mary University of London)H-Index: 28
Last.Sara Gandini (IEO: European Institute of Oncology)H-Index: 47
view all 9 authors...
Introduction: Obesity is a risk factor for postmenopausal breast cancer (BC) and evidence supports the pivotal role of adipokines in the association between obesity and BC. In the present study, we aim to investigate the role of adiponectin and leptin as independent risk markers for postmenopausal BC in a prospective nested case-control study within the cohort of women from the International Breast cancer Intervention prevention Study II (IBIS-II). Methods and Results: In the IBIS-II Prevention ...
#1H JohanssonH-Index: 1
#2Sara GandiniH-Index: 47
Last.Andrea DecensiH-Index: 36
view all 13 authors...
Background Polymorphisms of genes involved in estrogen production have been linked to breast cancer risk, prognosis and treatment response. Polymorphisms of the aromatase gene CYP19A1 influence its activity. The UGT2B17 catalyzes glucuronic acid transfer to a variety of substrates, including steroids and drugs like the aromatase inhibitor exemestane. We investigated the impact of two variants of CYP19A1 (rs10046, rs4646) and the UGT2B17 gene deletion on disease outcome in 125 postmenopausal wome...